The next chapter opened when SGLT2 antibodies and inhibitors became available, and we decided to study SGLT expression in fresh tumor samples collected from the operating room using protocols developed by Amy Yu and Bruce Hirayama [20, 22, 27]: First, we used viable tissue sections. The gene discussed is SLC5A2; the disease is neoplasm.